In the latest quarter, 13 analysts provided ratings for Incyte INCY, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 10 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 3 | 0 | 0 |
| 3M Ago | 1 | 1 | 5 | 0 | 0 |
Analysts have set 12-month price targets for Incyte, revealing an average target of $70.54, a high estimate of $92.00, and a low estimate of $60.00. This current average has increased by 2.69% from the previous average price target of $68.69.
Interpreting Analyst Ratings: A Closer Look
The analysis of recent analyst actions sheds light on the perception of Incyte by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jessica Fye | JP Morgan | Raises | Neutral | $65.00 | $61.00 |
| Derek Archila | Wells Fargo | Lowers | Equal-Weight | $62.00 | $63.00 |
| Srikripa Devarakonda | Truist Securities | Lowers | Hold | $74.00 | $83.00 |
| Michael Schmidt | Guggenheim | Raises | Buy | $92.00 | $86.00 |
| Tazeen Ahmad | B of A Securities | Raises | Neutral | $68.00 | $66.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $67.00 | $67.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $67.00 | $66.00 |
| James Shin | Deutsche Bank | Raises | Hold | $60.00 | $55.00 |
| David Lebowitz | Citigroup | Raises | Buy | $88.00 | $80.00 |
| Jessica Fye | JP Morgan | Raises | Neutral | $61.00 | $59.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $66.00 | $61.00 |
| Tazeen Ahmad | B of A Securities | Raises | Neutral | $66.00 | $62.00 |
| Jay Olson | Oppenheimer | Lowers | Outperform | $81.00 | $84.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Incyte. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Incyte's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
To gain a panoramic view of Incyte's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Incyte analyst ratings.
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Incyte: Financial Performance Dissected
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.34%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Incyte's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -42.6%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Incyte's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -10.6%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Incyte's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.54%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Incyte's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding the Relevance of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
